51.18 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||51.16 x 1300|
|Ask||51.23 x 900|
|Day's Range||51.11 - 51.57|
|52 Week Range||41.23 - 52.83|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||20.79|
|Forward Dividend & Yield||1.25 (2.44%)|
|1y Target Est||N/A|
PLAINSBORO, N.J., April 30, 2019 /PRNewswire/ -- Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero carbon emissions from operations and transportation. The announcement follows a $70 million investment in a 105-megawatt dc solar energy installation to be built in Pender County, North Carolina. When completed, ground-mounted solar arrays will harvest sunlight and provide renewable electricity to all existing Novo Nordisk US offices, laboratories and manufacturing facilities as well as to support the new manufacturing facility under construction in Clayton, N.C. Developed and constructed by Cypress Creek Renewables, the solar panel installation will be one of North Carolina's largest solar sites.
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®
Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.